Sep 12, 2022 / 11:00AM GMT
Boobalan Pachaiyappan - H.C. Wainwright & Co. - Analyst
Good morning and good afternoon, everyone. And thank you for joining the H.C. Wainwright 24th Annual Global Investment Hybrid Conference. My name is Boobalan Pachaiyappan. I'm H.C. Wainwright Vice President and Senior Analyst. With me today is Dr. Neal Walker, Co-Founder, Director, and CEO of Aclaris Therapeutics. Aclaris is focused on developing novel drugs for immuno-inflammatory diseases.
Neal, the floor is yours.
Neal Walker - Aclaris Therapeutics, Inc. - Co-Founder, CEO, & Director
Thank you. And thank you for having us. I'm Dr. Neal Walker. I'm the CEO of Aclaris. I'll be walking through an overview of the company for you today. So, Aclaris is a development-stage biotechnology company focused on the kinome and the development of small molecule therapeutics for immuno-inflammatory diseases. We have three key components to the company: the people -- we have a world-class ex-Pfizer kinase leadership with decades of experience looking at the kinome; we also have the KINect platform, which
Aclaris Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
